Eli Lilly & Co. (LLY) announced results from its Phase 3 EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease Monday afternoon. The results showed that patients with mild Alzheimer's disease taking solanezumab demonstrated a slowing of cognitive decline compared with placebo.
Eli Lilly & Co. climbed steadily following the release of the study results and finished up by 2.55 at $50.78 on strong volume. The stock has been rising for the past week and surged to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.